Cargando…
Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
AIMS/INTRODUCTION: Limited studies have identified risk factors linked to the progression of diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study examined the association of risk factors with change in neuropathy measures over 2 years. MATERIALS AND METHODS: Participants with type 2 d...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533053/ https://www.ncbi.nlm.nih.gov/pubmed/35652859 http://dx.doi.org/10.1111/jdi.13864 |
_version_ | 1784802258533220352 |
---|---|
author | Ponirakis, Georgios Al‐Janahi, Ibrahim Elgassim, Einas Gad, Hoda Petropoulos, Ioannis N Khan, Adnan Ali, Hamda Siddique, Mashhood A Gul, Wajiha Ferdousi, Maryam Kalteniece, Alise Mohamed, Fatima FS Ahmed, Lina HM Dakroury, Youssra El Shewehy, Abeer MM Al‐Mohamedi, Abdulrahman AlMarri, Fatema Homssi, Moayad Qazi, Murtaza Hadid, Nebras H Al‐Khayat, Fatima Mahfoud, Ziyad R Azmi, Shazli Alam, Uazman Zirie, Mahmoud A Al‐Ansari, Yousuf Jayyousi, Amin Rigby, Alan S Kilpatrick, Eric S Atkin, Stephen L Malik, Rayaz A |
author_facet | Ponirakis, Georgios Al‐Janahi, Ibrahim Elgassim, Einas Gad, Hoda Petropoulos, Ioannis N Khan, Adnan Ali, Hamda Siddique, Mashhood A Gul, Wajiha Ferdousi, Maryam Kalteniece, Alise Mohamed, Fatima FS Ahmed, Lina HM Dakroury, Youssra El Shewehy, Abeer MM Al‐Mohamedi, Abdulrahman AlMarri, Fatema Homssi, Moayad Qazi, Murtaza Hadid, Nebras H Al‐Khayat, Fatima Mahfoud, Ziyad R Azmi, Shazli Alam, Uazman Zirie, Mahmoud A Al‐Ansari, Yousuf Jayyousi, Amin Rigby, Alan S Kilpatrick, Eric S Atkin, Stephen L Malik, Rayaz A |
author_sort | Ponirakis, Georgios |
collection | PubMed |
description | AIMS/INTRODUCTION: Limited studies have identified risk factors linked to the progression of diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study examined the association of risk factors with change in neuropathy measures over 2 years. MATERIALS AND METHODS: Participants with type 2 diabetes (n = 78) and controls (n = 26) underwent assessment of clinical and metabolic parameters and neuropathy using corneal confocal microscopy (CCM), vibration perception threshold (VPT), and the DN4 questionnaire at baseline and 2 year follow‐up. RESULTS: Participants with type 2 diabetes had a lower corneal nerve fiber density (CNFD), branch density (CNBD), and fiber length (CNFL) (P ≤ 0.0001) and a higher VPT (P ≤ 0.01) compared with controls. Over 2 years, despite a modest reduction in HbA1c (P ≤ 0.001), body weight (P ≤ 0.05), and LDL (P ≤ 0.05) the prevalence of DPN (P = 0.28) and painful DPN (P = 0.21) did not change, but there was a significant further reduction in CNBD (P ≤ 0.0001) and CNFL (P ≤ 0.05). CNFD, CNBD, and CNFL decreased significantly in physically inactive subjects (P < 0.05–0.0001), whilst there was no change in CNFD (P = 0.07) or CNFL (P = 0.85) in physically active subjects. Furthermore, there was no change in CNFD (P = 0.82), CNBD (P = 0.08), or CNFL (P = 0.66) in patients treated with glucose lowering medication associated with weight loss, whilst CNBD (P = 0.001) decreased in patients on glucose lowering medication associated with weight gain. CONCLUSIONS: In participants with type 2 diabetes, despite a modest improvement in HbA1c, body weight, and LDL there was a progressive loss of corneal nerve fibers; except in those who were physically active or on glucose lowering medication associated with weight loss. |
format | Online Article Text |
id | pubmed-9533053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95330532022-10-11 Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes Ponirakis, Georgios Al‐Janahi, Ibrahim Elgassim, Einas Gad, Hoda Petropoulos, Ioannis N Khan, Adnan Ali, Hamda Siddique, Mashhood A Gul, Wajiha Ferdousi, Maryam Kalteniece, Alise Mohamed, Fatima FS Ahmed, Lina HM Dakroury, Youssra El Shewehy, Abeer MM Al‐Mohamedi, Abdulrahman AlMarri, Fatema Homssi, Moayad Qazi, Murtaza Hadid, Nebras H Al‐Khayat, Fatima Mahfoud, Ziyad R Azmi, Shazli Alam, Uazman Zirie, Mahmoud A Al‐Ansari, Yousuf Jayyousi, Amin Rigby, Alan S Kilpatrick, Eric S Atkin, Stephen L Malik, Rayaz A J Diabetes Investig Articles AIMS/INTRODUCTION: Limited studies have identified risk factors linked to the progression of diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study examined the association of risk factors with change in neuropathy measures over 2 years. MATERIALS AND METHODS: Participants with type 2 diabetes (n = 78) and controls (n = 26) underwent assessment of clinical and metabolic parameters and neuropathy using corneal confocal microscopy (CCM), vibration perception threshold (VPT), and the DN4 questionnaire at baseline and 2 year follow‐up. RESULTS: Participants with type 2 diabetes had a lower corneal nerve fiber density (CNFD), branch density (CNBD), and fiber length (CNFL) (P ≤ 0.0001) and a higher VPT (P ≤ 0.01) compared with controls. Over 2 years, despite a modest reduction in HbA1c (P ≤ 0.001), body weight (P ≤ 0.05), and LDL (P ≤ 0.05) the prevalence of DPN (P = 0.28) and painful DPN (P = 0.21) did not change, but there was a significant further reduction in CNBD (P ≤ 0.0001) and CNFL (P ≤ 0.05). CNFD, CNBD, and CNFL decreased significantly in physically inactive subjects (P < 0.05–0.0001), whilst there was no change in CNFD (P = 0.07) or CNFL (P = 0.85) in physically active subjects. Furthermore, there was no change in CNFD (P = 0.82), CNBD (P = 0.08), or CNFL (P = 0.66) in patients treated with glucose lowering medication associated with weight loss, whilst CNBD (P = 0.001) decreased in patients on glucose lowering medication associated with weight gain. CONCLUSIONS: In participants with type 2 diabetes, despite a modest improvement in HbA1c, body weight, and LDL there was a progressive loss of corneal nerve fibers; except in those who were physically active or on glucose lowering medication associated with weight loss. John Wiley and Sons Inc. 2022-06-20 2022-10 /pmc/articles/PMC9533053/ /pubmed/35652859 http://dx.doi.org/10.1111/jdi.13864 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Ponirakis, Georgios Al‐Janahi, Ibrahim Elgassim, Einas Gad, Hoda Petropoulos, Ioannis N Khan, Adnan Ali, Hamda Siddique, Mashhood A Gul, Wajiha Ferdousi, Maryam Kalteniece, Alise Mohamed, Fatima FS Ahmed, Lina HM Dakroury, Youssra El Shewehy, Abeer MM Al‐Mohamedi, Abdulrahman AlMarri, Fatema Homssi, Moayad Qazi, Murtaza Hadid, Nebras H Al‐Khayat, Fatima Mahfoud, Ziyad R Azmi, Shazli Alam, Uazman Zirie, Mahmoud A Al‐Ansari, Yousuf Jayyousi, Amin Rigby, Alan S Kilpatrick, Eric S Atkin, Stephen L Malik, Rayaz A Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
title | Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
title_full | Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
title_fullStr | Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
title_full_unstemmed | Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
title_short | Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
title_sort | progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533053/ https://www.ncbi.nlm.nih.gov/pubmed/35652859 http://dx.doi.org/10.1111/jdi.13864 |
work_keys_str_mv | AT ponirakisgeorgios progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT aljanahiibrahim progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT elgassimeinas progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT gadhoda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT petropoulosioannisn progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT khanadnan progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT alihamda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT siddiquemashhooda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT gulwajiha progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT ferdousimaryam progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT kalteniecealise progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT mohamedfatimafs progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT ahmedlinahm progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT dakrouryyoussra progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT elshewehyabeermm progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT almohamediabdulrahman progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT almarrifatema progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT homssimoayad progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT qazimurtaza progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT hadidnebrash progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT alkhayatfatima progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT mahfoudziyadr progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT azmishazli progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT alamuazman progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT ziriemahmouda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT alansariyousuf progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT jayyousiamin progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT rigbyalans progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT kilpatrickerics progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT atkinstephenl progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes AT malikrayaza progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes |